Lantheus (LNTH) said Wednesday its radiodiagnostic MK-6240 to treat Alzheimer's disease met its co-primary endpoints in two trials evaluating its sensitivity and specificity.
The results from the two trials will back a new drug application with the US Food and Drug Administration, which is expected to be filed in Q3, the company said.
MK-6240 was designed to complement Lantheus' imaging agent NAV-4694, which is in phase 3 development and is used in academic and industry-led investigational trials for Alzheimer's disease, the company said.
The company's shares were down 0.5% in recent trading.
Price: 103.00, Change: -0.96, Percent Change: -0.93
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。